• Nausea

Barhemsys Generic Name & Formulations

General Description

Amisulpride 2.5mg/mL; soln for IV infusion.

Pharmacological Class

Dopamine-2 receptor antagonist.

How Supplied

Single-dose vial (2mL)—10


Generic Availability


Barhemsys Indications


Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.

Barhemsys Dosage and Administration


Prevention: 5mg as a single IV inj infused over 1–2mins at the time of induction of anesthesia. Treatment: 10mg as a single IV inj infused over 1–2mins in the event of nausea and/or vomiting after a surgical procedure.


Not established.

Barhemsys Contraindications

Not Applicable

Barhemsys Boxed Warnings

Not Applicable

Barhemsys Warnings/Precautions


Risk of QT prolongation. Avoid in congenital long QT syndrome. Monitor ECG in those with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), CHF, or other medical conditions known to prolong the QT interval. Severe renal impairment (eGFR <30mL/min/1.73m2): avoid. Pregnancy. Nursing mothers: consider interrupting breastfeeding or pumping/discarding breast milk for 48hrs after dose.

Barhemsys Pharmacokinetics

See Literature

Barhemsys Interactions


Avoid concomitant droperidol, levodopa. Concomitant other drugs known to prolong the QT interval (eg, ondansetron): monitor ECG.

Barhemsys Adverse Reactions

Adverse Reactions

Increased blood prolactin concentrations, chills, hypokalemia, procedural hypotension, abdominal distension, infusion site pain.

Barhemsys Clinical Trials

See Literature

Barhemsys Note

Not Applicable

Barhemsys Patient Counseling

See Literature